论文部分内容阅读
目的:探讨瑞舒伐他汀和阿托伐他汀对冠心病患者的调脂效果。方法:选取2014年10月-2015年1月收治的冠心病患者50例作为研究对象,随机分成观察组(给予瑞舒伐他汀25例,10mg/次,1次/d),对照组(阿托伐他汀组各25例,10mg/次,1次/d),两组均以4周为1疗程,治疗1疗程后观察和比较两组临床疗效;TC、TG、LDL-C、HDL-C变化情况。结果:观察组与对照组总有效率分别为96.0%(24/25)与84.0%(21/25),两组比较差异有统计学意义(x2=6.012,P<0.05)。治疗前两组TC、TG、LDL-C、HDL-C水平比较,差异无显著性差异(P>0.05);治疗后两组TC、TG、LDL-C、HDL-C水平与同组治疗前比较,差异具有显著性意义(P<0.05);治疗后两组TC、TG、LDL-C、HDL-C水平比较,观察组显著优于对照组,两组比较具有显著性意义(P<0.05)。结论:在临床治疗冠心病患者的实践过程中,采用瑞舒伐他汀治疗冠心病比阿托伐他汀,具有提高临床疗效及较好的调脂效果,有临床推广应用的价值。
Objective: To investigate rosuvastatin and atorvastatin on patients with coronary heart disease lipid-regulating effect. Methods: Fifty patients with coronary heart disease who were admitted from October 2014 to January 2015 were randomly divided into observation group (given rosuvastatin 25, 10 mg / time, once a day) and control group TCT, TG, LDL-C and HDL-C were all observed in the two groups after treatment for one course of treatment. C changes. Results: The total effective rate in observation group and control group was 96.0% (24/25) and 84.0% (21/25), respectively. The difference between the two groups was statistically significant (x2 = 6.012, P <0.05). The levels of TC, TG, LDL-C and HDL-C in the two groups before treatment had no significant difference (P> 0.05). After treatment, the levels of TC, TG, LDL- (P <0.05). After treatment, the levels of TC, TG, LDL-C and HDL-C in the two groups were significantly better than those in the control group, the two groups had significant difference (P <0.05 ). Conclusion: In the clinical practice of patients with coronary heart disease, the use of rosuvastatin in treatment of coronary heart disease compared with atorvastatin, with improved clinical efficacy and better lipid-lowering effect, the clinical application of the value.